{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -3.1249971, "regularMarketPrice": 0.62, "earningsTimestamp": 1683808200, "earningsTimestampStart": 1691584200, "earningsTimestampEnd": 1692016200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.16, "sharesOutstanding": 15124100, "bookValue": 3.427, "fiftyDayAverage": 0.6729, "fiftyDayAverageChange": -0.052900016, "fiftyDayAverageChangePercent": -0.07861497, "twoHundredDayAverage": 0.869055, "twoHundredDayAverageChange": -0.24905497, "twoHundredDayAverageChangePercent": -0.28658137, "marketCap": 9520906, "priceToBook": 0.18091625, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Synthetic Biologics, Inc.", "nameChangeDate": "2023-05-11", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1198825200000, "priceHint": 4, "marketState": "REGULAR", "exchange": "FRA", "shortName": "THERIVA BIOLOGICS DL-,001", "longName": "Theriva Biologics, Inc.", "messageBoardId": "finmb_24424557", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": -0.01999998, "regularMarketTime": 1683872402, "regularMarketDayHigh": 0.62, "regularMarketDayRange": "0.62 - 0.62", "regularMarketDayLow": 0.62, "regularMarketVolume": 1, "regularMarketPreviousClose": 0.64, "bid": 0.635, "ask": 0.655, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.62, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.4932, "fiftyTwoWeekLowChangePercent": 3.88959, "fiftyTwoWeekRange": "0.1268 - 2.151", "fiftyTwoWeekHighChange": -1.531, "fiftyTwoWeekHighChangePercent": -0.71176195, "fiftyTwoWeekLow": 0.1268, "fiftyTwoWeekHigh": 2.151, "symbol": "SFY.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9605 Medical Center Drive", "address2": "Suite 270", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "301 417 4364", "website": "https://therivabio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral \u00df-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.", "fullTimeEmployees": 21, "companyOfficers": [{"maxAge": 1, "name": "Mr. Steven A. Shallcross CPA", "age": 61, "title": "CEO, CFO, Treasurer, Corp. Sec. & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 997674, "fmt": "997.67k", "longFmt": "997,674"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Frank  Tufaro Ph.D.", "age": 66, "title": "Chief Operating Officer", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 485797, "fmt": "485.8k", "longFmt": "485,797"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Vincent I. Perrone", "title": "Director of Corp. Communication", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Vince  Wacher Ph.D.", "title": "Head of Product and Corp. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Kaleko M.D., Ph.D.", "title": "Sr. VP of R&D", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lara M. Guzman", "title": "Sr. Director of Project Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}